Pentadeca Arginate

PDA, BPC-157 arginate, BPC-157 arginine salt, pentadecapeptide arginate

Recovery, repair & tissue

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Summary

Class: Synthetic 15-amino-acid peptide; the same amino-acid sequence as BPC-157, supplied as an arginine salt rather than the usual acetate salt
Mechanism: Presumed identical to BPC-157 — angiogenesis, growth-factor and nitric-oxide signalling in rodent models — because the active peptide is the same; no PDA-specific mechanism work exists
Routes studied: None published for PDA. Community: subcutaneous injection, oral capsules
Dose range reported: No study doses exist. Community reports: 250–1,000 µg/day subcutaneous, or 500 µg oral capsules, mirroring BPC-157 practice
Half-life: Not characterised. BPC-157's own human half-life is also unknown
Storage: Lyophilised: refrigerate, protect from light. Reconstituted: refrigerate; community practice is use within ~4 weeks. Marketed as more stable than the acetate form; this claim has not been independently tested
Regulatory status: Not approved for human use anywhere. See region table

Doses are as reported in studies or by the community — never recommendations.

1What it is

Pentadeca Arginate is a salt form of BPC-157. The peptide chain — the part that does anything in the body — is the same 15 amino acids. What differs is the counter-ion attached to the powder: arginine instead of acetate. Salt forms can change how a powder dissolves and how stable it is on the shelf, but once in solution the peptide is BPC-157.

The name appeared in the market around 2023–2024, shortly after the US FDA placed BPC-157 in Category 2 of its compounding bulk-substances list. It is reasonable to read the renaming as a response to that listing. There are no peer-reviewed papers that use the term "pentadeca arginate", and no published study has compared the arginate and acetate forms for stability, absorption or effect.

This profile therefore has to lean entirely on the BPC-157 literature, and everything said about that compound — a single dominant research group, almost all rodent data, one small uncontrolled human series — applies here. See the BPC-157 profile for the detail.

2How it's thought to work

Assumed to be the same as BPC-157, based on rodent and cell studies of the parent peptide:

Promotes new blood-vessel growth (), with work implicating VEGFR2 and nitric-oxide pathways.

Raises expression of growth factors and receptors involved in tendon and ligament repair.

Protects the gut lining from NSAID and alcohol injury in rodent models.

Interacts with dopamine and serotonin systems in rodents.

Proposed: new capillaries grow toward the injury; fibroblasts lay down aligned collagen.Schematic — not to scale

Marketing material sometimes claims the arginine salt improves stability or bioavailability. Arginine is a common pharmaceutical counter-ion and this is plausible in principle, but no data has been published to show it for this peptide.

3What the research shows

Any effect of PDA specifically

No published animal or human study exists under this name. All claims are extrapolated.

Tendon, ligament, muscle healing (BPC-157 literature)

Rat models of transected Achilles tendon, medial collateral ligament and crushed muscle report faster healing (Staresinic 2003, J Orthop Res; Krivic 2006, J Orthop Res; Chang 2011, J Appl Physiol). All rodent or cell-based, almost all from one research group in Zagreb. [2][3][4]

Gut protection (BPC-157 literature)

Extensive rodent work on NSAID ulcers, colitis and fistula models (Sikiric 2010, Curr Pharm Des review). Not replicated in humans in published form. [1]

Knee pain (BPC-157 literature)

A 12-patient retrospective case series of intra-articular BPC-157 (Lee & Padgett 2021, Altern Ther Health Med). Small, uncontrolled, single clinic. [5]

Stability or absorption advantage of the arginate form

Claimed commercially; untested in any published work.

4Reported side effects and interactions

Literature-reported

None for PDA. For BPC-157: almost no human safety data; rodent studies report few adverse effects at tested doses. The mechanism raises a theoretical concern about existing tumours.

Community-reported

injection-site redness, occasional nausea, dizziness or headache — the same pattern reported for BPC-157. Some members report the arginate powder dissolves more readily; this is anecdotal.

Theoretical. arginine itself is a nitric-oxide precursor, but the amount in a microgram dose of peptide salt is nutritionally trivial. A salt change should not alter toxicity, but the absence of data means this is assumed, not shown.

Interactions. none established. Rodent work on BPC-157 suggests interaction with dopaminergic drugs; relevance to humans unknown.

Markers researchers commonly monitor

No compound-specific markers are established for PDA or for BPC-157. Protocols that include it generally record:

Marker	Why it's watched
Baseline CBC and CMP	general safety monitoring in the absence of any specific signal.
Injury-specific functional measures (range of motion, pain scores, imaging where relevant)	because the main community use is soft-tissue recovery and there is no biochemical marker of effect.
Blood pressure	rodent work reports effects on vascular tone; no human relevance shown.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Typically supplied as powder in 5 mg or 10 mg vials. with , swirl gently, protect from light. Because the salt form changes the molecular weight slightly, a "5 mg" vial of arginate contains marginally less peptide than a 5 mg vial of acetate; the difference is small and the calculator uses the labelled amount.

Open in calculator, pre-loaded →

6Commonly studied alongside

TB-500 and GHK-Cu (community injury-recovery stacks, carried over from BPC-157 practice; no combined study), KPV.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Not FDA-approved. BPC-157 is in Category 2 of the FDA's 2023 compounding bulk-substances list; whether the arginate salt is treated as the same substance has not been stated explicitly by FDA, but the listing is based on the active peptide †
European Union	Not authorised as a medicine; not a permitted food or supplement ingredient
United Kingdom	Not licensed
Australia	Not an approved product; BPC-157 falls under prescription-only scheduling †
South Africa	Not registered with SAHPRA
Sport	Prohibited by WADA (S0 — non-approved substances); the salt form makes no difference to the ban

8Open questions

Does the arginate salt actually differ from the acetate form in stability, solubility or absorption? No published comparison.
Every open question for BPC-157 — oral bioavailability in humans, independent replication, long-term safety — applies unchanged.
Will regulators treat the renamed salt as the same substance as BPC-157?

9References

1Sikiric P et al. (2010). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. PubMed · DOI
2Staresinic M et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. PubMed · DOI
3Krivic A et al. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res. PubMed
4Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. PubMed · DOI
5Lee E, Padgett B (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. PubMed
6FDA (2023). Certain bulk drug substances for use in compounding that may present significant safety risks — BPC-157. PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

25 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.